Catatonia Associated with Initiating Paliperidone Treatment

We present a case of catatonia, which occurred shortly after starting a new antipsychotic, paliperidone, an active metabolite of risperidone. Catatonia may be caused by a variety of conditions, including metabolic, neurologic, psychiatric and toxic processes. Interestingly, risperidone, which has be...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeown, Nathanael J., Bryan, James H., Horowitz, B Zane
Formato: Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2010
Materias:
Neurobehavioral
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908655/
https://www.ncbi.nlm.nih.gov/pubmed/20823970
_version_ 1782184214358130688
author McKeown, Nathanael J.
Bryan, James H.
Horowitz, B Zane
author_facet McKeown, Nathanael J.
Bryan, James H.
Horowitz, B Zane
author_sort McKeown, Nathanael J.
collection PubMed
description We present a case of catatonia, which occurred shortly after starting a new antipsychotic, paliperidone, an active metabolite of risperidone. Catatonia may be caused by a variety of conditions, including metabolic, neurologic, psychiatric and toxic processes. Interestingly, risperidone, which has been thought to cause several cases of catatonia, has also been recommended as a potential treatment. We discuss potential mechanisms for causes of drug-induced catatonia as well as potential treatment options.
format Text
id pubmed-2908655
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Department of Emergency Medicine, University of California, Irvine School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-29086552010-09-07 Catatonia Associated with Initiating Paliperidone Treatment McKeown, Nathanael J. Bryan, James H. Horowitz, B Zane West J Emerg Med Neurobehavioral We present a case of catatonia, which occurred shortly after starting a new antipsychotic, paliperidone, an active metabolite of risperidone. Catatonia may be caused by a variety of conditions, including metabolic, neurologic, psychiatric and toxic processes. Interestingly, risperidone, which has been thought to cause several cases of catatonia, has also been recommended as a potential treatment. We discuss potential mechanisms for causes of drug-induced catatonia as well as potential treatment options. Department of Emergency Medicine, University of California, Irvine School of Medicine 2010-05 /pmc/articles/PMC2908655/ /pubmed/20823970 Text en Copyright © 2010 the authors. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Neurobehavioral
McKeown, Nathanael J.
Bryan, James H.
Horowitz, B Zane
Catatonia Associated with Initiating Paliperidone Treatment
title Catatonia Associated with Initiating Paliperidone Treatment
title_full Catatonia Associated with Initiating Paliperidone Treatment
title_fullStr Catatonia Associated with Initiating Paliperidone Treatment
title_full_unstemmed Catatonia Associated with Initiating Paliperidone Treatment
title_short Catatonia Associated with Initiating Paliperidone Treatment
title_sort catatonia associated with initiating paliperidone treatment
topic Neurobehavioral
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908655/
https://www.ncbi.nlm.nih.gov/pubmed/20823970
work_keys_str_mv AT mckeownnathanaelj catatoniaassociatedwithinitiatingpaliperidonetreatment
AT bryanjamesh catatoniaassociatedwithinitiatingpaliperidonetreatment
AT horowitzbzane catatoniaassociatedwithinitiatingpaliperidonetreatment

Ejemplares similares